Tailor-made therapy for cancer based on tumor angiogenesis and hypoxia

• Project/Area Number: 21591772
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Kyoto University
• Principal Investigator: MORI Akira 京都大学, 医学研究科, 非常勤講師 (60324646)
• Co-Investigator(Kenkyū-buntansha): HATA Koichiro 京都大学, 医学研究科, 助教 (90523118)
• Project Period (FY): 2009 – 2011
• Project Status: Completed (Fiscal Year 2011)
• Budget Amount: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000); Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: 腫瘍血管新生 / 低酸素 / 分子標的治療 / 膵癌 / 肝細胞癌 / 肝移植 / 癌 / 血管新生 / KLF5 / HIF-1α / HIF-1

Research Abstract

Kruppel-like factor 5(KLF5) is a transcription factor involved in cell transformation, proliferation, and carcinogenesis that can be up-regulated by RAS mutations. However, controversy persists as to whether it functions as a tumor suppressor or as an oncogene. The overexpression of KLF5 in human pancreatic cancer cells is not mediated by KRAS/Raf/MAPK/Erk signaling, but involves the IL-1beta/IL-1R system, p38, and the transcription factor HIF-1alpha. KLF5 is a promising candidate of target molecule in pancreatic cancer therapy. We are now investigating the clinical significance of KLF5 in pancreatic cancer patients.

Research Products

• [Journal Article] Up-regulation of Kruppel-like factor 5in pancreatic cancer is promoted byinterleukin-1beta signaling and hypoxia-inducible factor-1alpha (2009)
  • Author(s): Mori A, Moser C, Lang SA, et al.
  • Journal Title: Mol Cancer Res Volume: 7 Issue: 8 Pages: 1390-1398
  • DOI: 10.1158/1541-7786.mcr-08-0525
  • Peer Reviewed
• [Journal Article] Up-regulation of Kruppel-like factor 5 in pancereatic cancer is promoted by interleukin-1beta signaling and hypoxia-inducible factor-1alpha. (2009)
  • Author(s): Mori A, Moser C, Lang SA, et al.
  • Journal Title: Molecular Cancer Research 7 Pages: 1390-1398
  • Peer Reviewed
• [Presentation] 膵癌におけるKLF5のシグナル伝達経路と治療標的としての可能性 (2009)
  • Author(s): 森章、Oliver Stoeltzing、土井隆一郎、上本伸二
  • Organizer: 第68回日本癌学会学術総会
  • Place of Presentation: 横浜
  • Year and Date: 2009-10-02
• [Presentation] 膵癌におけるKLF5のシグナル伝達経路と治療標的としての可能性 (2009)
  • Author(s): 森章
  • Organizer: 第68回 日本癌学会学術総会
  • Place of Presentation: 横浜
  • Year and Date: 2009-10-02
• [Presentation] 膵癌におけるKLF5のシグナル伝達経路と治療標的としての可能性 (2009)
  • Author(s): 森章、Oliver Stoeltzing、土井隆一郎、上本伸二
  • Organizer: 第18回日本癌転移学会学術集会・総会
  • Place of Presentation: 旭川
  • Year and Date: 2009-07-23